This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Erdmann, E. Search for Related Content PubMed Articles by Erdmann, E. Social Bookmarking                         What's this?

The Benefits of Angiotensin Receptor Blockers in Patients with Chronic Heart Failure and Multiple Co-morbidities

Department of Cardiology, University of Cologne, Cologne, Germany, erland.erdmann{at}uni-koeln.de

Chronic heart failure (CHF) is common among the elderly, who typically suffer from multiple co-morbidities.The clinician therefore needs to consider the possibility of interaction between drugs given to treat these underlying conditions and drugs given to treat CHF. Patients who remain symptomatic despite established CHF therapy derive important clinical benefits from the addition of an angiotensin receptor blocker (ARB), irrespective of age, sex, ethnicity and baseline heart failure, as recognised in the recent revision of the European Society of Cardiology guidelines for the treatment of CHF.

Rationalisation of concomitant therapy in accordance with guideline recommendations can help to minimise the potential for adverse effects.

This case report describes an elderly man with CHF and multiple co-morbidities who remained symptomatic despite established therapy.

Key Words: Chronic heart failure • Co-morbidity • Rationalisation • Candesartan

References

• Bleumink GS, Knetsch AM, Sturkenboom MC et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 2004;25:1614-19.[Abstract/Free Full Text]
• Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.[Abstract/Free Full Text]
• Swedberg K., Cleland J., Dargie H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Taskforce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.[Free Full Text]
• Adams KF, Patterson JH, Gattis WA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial: a retrospective analysis. J Am Coll Cardiol 2005;46:497-504.[Abstract/Free Full Text]
• McMurray JJV, Östergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM Low-Left Ventricular Ejection Fraction Trials. Circulation 2004;110:2618-26.[Abstract/Free Full Text]
• Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.[Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2 suppl, S11-S12 (2005)
DOI: 10.1177/14703203050060020401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Erdmann, E. Search for Related Content PubMed Articles by Erdmann, E. Social Bookmarking                         What's this?